Illangeswaran RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, Rajamani BM, Janet NB, et al. Chemotherapeutic medication elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell traces. Leuk Res. 2023;128:107054.
Chen Y, Zou Z, Găman MA, Xu L, Li J. NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia. Cell Demise Discov. 2023;9:208.
Visser N, Lourens HJ, Huls G, Bremer E, Wiersma VR. Inhibition of autophagy doesn’t re-sensitize acute myeloid leukemia cells immune to cytarabine. Int J Mol Sci. 2021;22:2337.
Putyrski M, Vakhrusheva O, Bonn F, Guntur S, Vorobyov A, Brandts C, et al. Disrupting the LC3 interplay area (LIR) binding of selective autophagy receptors sensitizes AMl cell traces to cytarabine. Entrance Cell Dev Biol. 2020;8:208.
Dykstra KM, Fay HRS, Massey AC, Yang N, Johnson M, Portwood S, et al. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv. 2021;5:2087–100.
Huang L, Lin L, Fu X, Meng C. Growth and validation of a novel survival mannequin for acute myeloid leukemia based mostly on autophagy-related genes. PeerJ. 2021;9:e11968.
Koschade SE, Klann Ok, Shaid S, Vick B, Stratmann JA, Thölken M, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022;36:2396–407.
Rodriguez-Zabala M, Ramakrishnan R, Reinbach Ok, Ghosh S, Oburoglu L, Falqués-Costa A, et al. Mixed GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Adv. 2023:2023009967.
Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, et al. Oncogenic FLT3-ITD helps autophagy by way of ATF4 in acute myeloid leukemia. Oncogene. 2018;37:787–97.
Adelipour M, Saleth LR, Ghavami S, Alagarsamy KN, Dhingra S, Allameh A. The position of autophagy within the metabolism and differentiation of stem cells. Biochim Biophys Acta Mol Foundation Dis. 2022;1868:166412.
Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular goal for most cancers therapy. Eur J Pharm Sci. 2019;134:116–37.
Chen YF, Liu H, Luo XJ, Zhao Z, Zou ZY, Li J, et al. The roles of reactive oxygen species (ROS) and autophagy within the survival and demise of leukemia cells. Crit Rev Oncol Hematol. 2017;112:21–30.
Gomez-Puerto MC, Folkerts H, Wierenga AT, Schepers Ok, Schuringa JJ, Coffer PJ, et al. Autophagy proteins ATG5 and ATG7 are important for the upkeep of human CD34(+) hematopoietic stem-progenitor cells. Stem Cells. 2016;34:1651–63.
Jung HE, Shim YR, Oh JE, Oh DS, Lee HK. The autophagy protein Atg5 performs a vital position within the upkeep and reconstitution skill of hematopoietic stem cells. Immune Netw. 2019;19:e12.
Cao Y, Zhang A, Cai J, Yuan N, Lin W, Liu S, et al. Autophagy regulates the cell cycle of murine HSPCs in a nutrient-dependent method. Exp Hematol. 2015;43:229–42.
Nomura N, Ito C, Ooshio T, Tadokoro Y, Kohno S, Ueno M, et al. Important position of autophagy in defending neonatal haematopoietic stem cells from oxidative stress in a p62-independent method. Sci Rep. 2021;11:1666.
Chen Y, Luo X, Zou Z, Liang Y. The position of reactive oxygen species in tumor therapy and its impression on bone marrow hematopoiesis. Curr Drug Targets. 2020;21:477–98.
Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is crucial for hematopoietic stem cell upkeep. J Exp Med. 2011;208:455–67.
Cao Y, Cai J, Zhang S, Yuan N, Fang Y, Wang Z, et al. Autophagy sustains hematopoiesis via concentrating on Notch. Stem Cells Dev. 2015;24:2660–73.
Khan A, Singh VK, Thakral D, Gupta R. Autophagy in acute myeloid leukemia: a paradoxical position in chemoresistance. Clin Transl Oncol. 2022;24:1459–69.
Sharma P, Piya S, Baran N, et al. Inhibition of ERK1/2 reverses venetoclax-induced autophagy to beat resistance in acute myeloid leukemia. Blood. 2022;140:3093–94.
Folkerts H, Wierenga AT, van den Heuvel FA, Woldhuis RR, Kluit DS, Jaques J, et al. Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protecting in opposition to venetoclax-induced apoptosis. Cell Demise Dis. 2019;10:421.
Sumitomo Y, Koya J, Nakazaki Ok, Kataoka Ok, Tsuruta-Kishino T, Morita Ok, et al. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. Blood. 2016;128:1614–24.
Hu X, Mei S, Meng W, Xue S, Jiang L, Yang Y, et al. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance. Most cancers Lett. 2018;425:1–12.
Haghi A, Salemi M, Fakhimahmadi A, Mohammadi Kian M, Yousefi H, Rahmati M, et al. Results of various autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy. IUBMB Life. 2021;73:130–45.
Badr G, Zahran AM, Omar HM, Barsoum MA, Mahmoud MH. Camel whey protein disrupts the cross-talk between PI3K and BCL-2 alerts and mediates apoptosis in main acute myeloid leukemia cells. Nutr Most cancers. 2019;71:1040–54.
Zhang Y, Li J, Shi W. Metformin inhibits acute myeloid leukemia cells progress via the AMPK/mTOR pathway and autophagic regulation. Blood. 2022;140:6175–75.
Siedlecka-Kroplewska Ok, Wozniak M, Kmiec Z. The wine polyphenol resveratrol modulates autophagy and induces apoptosis in MOLT-4 and HL-60 human leukemia cells. J Physiol Pharm. 2019;70:e792.
Xiao J, Zhang B, Yin S, Xie S, Huang Ok, Wang J, et al. Quercetin induces autophagy-associated demise in HL-60 cells via CaMKKβ/AMPK/mTOR sign pathway. Acta Biochim Biophys Sin (Shanghai). 2022;54:1244–56.
Ma H, Liu Y, Miao Z, Cheng S, Zhu Y, Wu Y, et al. Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy-dependent ferroptosis. Drug Dev Res. 2022;83:1641–53.
Orfali N, O’Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, et al. Induction of autophagy is a key part of all-trans-retinoic acid-induced differentiation in leukemia cells and a possible goal for pharmacologic modulation. Exp Hematol. 2015;43:781–93.e2.
Du Y, Bao J, Zhang MJ, Li LL, Xu XL, Chen H, et al. Concentrating on ferroptosis contributes to ATPR-induced AML differentiation by way of ROS-autophagy-lysosomal pathway. Gene. 2020;755:144889.
Warburg O. On the origin of most cancers cells. Science. 1956;123:309–14.
Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Rising roles and the regulation of cardio glycolysis in hepatocellular carcinoma. J Exp Clin Most cancers Res. 2020;39:126.
Ruocco MR, Avagliano A, Granato G, Vigliar E, Masone S, Montagnani S, et al. Metabolic flexibility in melanoma: a possible therapeutic goal. Semin Most cancers Biol. 2019;59:187–207.
Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, et al. A definite glucose metabolism signature of acute myeloid leukemia with prognostic worth. Blood. 2014;124:1645–54.
Zhu Y, Liu Z, Wan Y, Zou L, Liu L, Ding S, et al. PARP14 promotes the expansion and glycolysis of acute myeloid leukemia cells by regulating HIF-1α expression. Clin Immunol. 2022;242:109094.
Lapa B, Gonçalves AC, Jorge J, Alves R, Pires AS, Abrantes AM, et al. Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis confirmed to be a greater therapeutic goal. Med Oncol. 2020;37:72.
Wang YH, Israelsen WJ, Lee D, Yu VWC, Jeanson NT, Clish CB, et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014;158:1309–23.
Chen S, Tao Y, Wang Q, Ren J, Jing Y, Huang J, et al. Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia. Leuk Res. 2023;128:107059.
Chen WL, Wang YY, Zhao A, Xia L, Xie G, Su M, et al. Enhanced fructose utilization mediated by SLC2A5 is a novel metabolic characteristic of acute myeloid leukemia with therapeutic potential. Most cancers Cell. 2016;30:779–91.
Rai Y, Yadav P, Kumari N, Kalra N, Bhatt AN. Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells Ok-562 to anti-leukemic drug, daunorubicin. Biosci Rep. 2019;39:BSR20190880.
Lin G, Wu Y, Cai F, Li Z, Su S, Wang J, et al. Matrine promotes human myeloid leukemia cells apoptosis via warburg impact mediated by hexokinase 2. Entrance Pharm. 2019;10:1069.
Feng Y, Wu L. mTOR up-regulation of PFKFB3 is crucial for acute myeloid leukemia cell survival. Biochem Biophys Res Commun. 2017;483:897–903.
Roma A, Tcheng M, Ahmed N, et al. Shikonin impairs mitochondrial exercise to selectively goal leukemia cells. Phytomedicine. 2022;2:100300.
Ji Q, Ding YH, Solar Y, Zhang Y, Gao HE, Music HN, et al. Antineoplastic results and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget. 2016;7:65012–23.
Qin L, Tian Y, Yu Z, Shi D, Wang J, Zhang C, et al. Concentrating on PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell progress. Oncotarget. 2016;7:1395–407.
Chen Y, Xu Q, Ji D, Wei Y, Chen H, Li T, et al. Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia. Tumour Biol. 2016;37:6027–34.
Ju HQ, Zhan G, Huang A, Solar Y, Wen S, Yang J, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg impact and renders therapeutic sensitivity to glycolytic inhibition. Leukemia. 2017;31:2143–50.
Robinson AJ, Hopkins GL, Rastogi N, Hodges M, Doyle M, Davies S, et al. Reactive oxygen species drive proliferation in acute myeloid leukemia by way of the glycolytic regulator PFKFB3. Most cancers Res. 2020;80:937–49.
Hara Y, Shiba N, Yoshida Ok, Yamato G, Kaburagi T, Shiraishi Y, et al. TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia. Genes Chromosomes Most cancers. 2023;62:412–22.
Chu X, Zhong L, Dan W, Wang X, Zhang Z, Liu Z, et al. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis via the NRF2/NQO1 axis. Cell Sign. 2023;105:110626.
Watson AS, Riffelmacher T, Stranks A, Williams O, De Boer J, Cain Ok, et al. Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia. Cell Demise Discov. 2015;1:15008.
Baker F, Polat IH, Abou-El-Ardat Ok, Alshamleh I, Thoelken M, Hymon D, et al. Metabolic rewiring is crucial for aml cell survival to beat autophagy inhibition by lack of ATG3. Cancers (Basel). 2021;13:6142.
Feng Y, Liu J, Guo W, Guan Y, Xu H, Guo Q, et al. Atg7 inhibits Warburg impact by suppressing PKM2 phosphorylation ensuing decreased epithelial-mesenchymal transition. Int J Biol Sci. 2018;14:775–83.
Robert G, Jacquel A, Auberger P. Chaperone-mediated autophagy and its rising position in hematological malignancies. Cells. 2019;8:1260.
Xia HG, Najafov A, Geng J, Galan-Acosta L, Han X, Guo Y, et al. Degradation of HK2 by chaperone-mediated autophagy promotes metabolic disaster and cell demise. J Cell Biol. 2015;210:705–16.
Ouchida AT, Li Y, Geng J, Najafov A, Ofengeim D, Solar X, et al. Synergistic impact of a novel autophagy inhibitor and Quizartinib enhances most cancers cell demise. Cell Demise Dis. 2018;9:138.
Yan RL, Chen RH. Autophagy and most cancers metabolism-The 2-way interaction. IUBMB Life. 2022;74:281–95.
Wang L, Yang L, Yang Z, Tang Y, Tao Y, Zhan Q, et al. Glycolytic enzyme PKM2 mediates autophagic activation to advertise cell survival in NPM1-mutated leukemia. Int J Biol Sci. 2019;15:882–94.
Kawaguchi M, Aoki S, Hirao T, Morita M, Ito Ok. Autophagy is a vital metabolic pathway to find out leukemia cell survival following suppression of the glycolytic pathway. Biochem Biophys Res Commun. 2016;474:188–92.
Chu Y, Chang Y, Lu W, Sheng X, Wang S, Xu H, et al. Regulation of autophagy by glycolysis in most cancers. Most cancers Manag Res. 2020;12:13259–71.
Roberts DJ, Tan-Sah VP, Ding EY, Smith JM, Miyamoto S. Hexokinase-II positively regulates glucose starvation-induced autophagy via TORC1 inhibition. Mol Cell. 2014;53:521–33.
Music BH, Son SY, Kim HK, Ha TW, Im JS, Ryu A, et al. Profiling of metabolic variations between hematopoietic stem cells and acute/persistent myeloid leukemia. Metabolites. 2020;10:427.
Chen Y, Li J, Xu L, Găman MA, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells within the microenvironment: From biology to therapeutic concentrating on. Cell Demise Discov. 2022;8:397.
Kikushige Y, Miyamoto T, Kochi Y, Semba Y, Ohishi M, Irifune H, et al. Human acute leukemia makes use of branched-chain amino acid catabolism to keep up stemness via regulating PRC2 perform. Blood Adv. 2023;7:3592–603.
Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Most cancers Cell. 2018;34:724–40.e4.
Jones CL, Stevens BM, D’Alessandro A, Culp-Hill R, Reisz JA, Pei S, et al. Cysteine depletion targets leukemia stem cells via inhibition of electron transport advanced II. Blood. 2019;134:389–94.
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts vitality metabolism and targets leukemia stem cells in sufferers with acute myeloid leukemia. Nat Med. 2018;24:1859–66.
Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, et al. Concentrating on glutamine metabolism and redox state for leukemia remedy. Clin Most cancers Res. 2019;25:4079–90.
Dai YJ, Hu F, He SY, et al. A definite metabolic signature in DNMT3A-mutated leukemia. Blood. 2019;134:1426.
Xiao Y, Hu B, Guo Y, Zhang D, Zhao Y, Chen Y, et al. Concentrating on glutamine metabolism as a beautiful therapeutic technique for acute myeloid leukemia. Curr Deal with Choices Oncol. 2023;24:1021–35.
Wang D, Tan G, Wang H, Chen P, Hao J, Wang Y. Identification of novel serum biomarker for the detection of acute myeloid leukemia based mostly on liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2019;166:357–63.
Rex MR, Williams R, Birsoy Ok, Ta Llman MS, Stahl M. Concentrating on mitochondrial metabolism in acute myeloid leukemia. Leuk Lymphoma. 2022;63:530–7.
Lee SW, Zhang Y, Jung M, Cruz N, Alas B, Commisso C. EGFR-Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis. Dev Cell. 2019;50:381–92.e5.
Fulton TL, Mirth CK, Piper MDW. Proscribing a single amino acid cross-protects Drosophila melanogaster from nicotine poisoning via mTORC1 and GCN2 signalling. Open Biol. 2022;12:220319.
Timosenko E, Ghadbane H, Silk JD, Shepherd D, Gileadi U, Howson LJ, et al. Dietary stress induced by tryptophan-degrading enzymes leads to ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells. Most cancers Res. 2016;76:6193–204.
Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab. 2013;304:E789–99.
B’chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, et al. The eIF2α/ATF4 pathway is crucial for stress-induced autophagy gene expression. Nucleic Acids Res. 2013;41:7683–99.
Nakamura A, Nambu T, Ebara S, Hasegawa Y, Toyoshima Ok, Tsuchiya Y, et al. Inhibition of GCN2 sensitizes ASNS-low most cancers cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci USA. 2018;115:E7776–85.
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, et al. Inhibiting glutamine uptake represents a beautiful new technique for treating acute myeloid leukemia. Blood. 2013;122:3521–32.
Bhingarkar A, Vangapandu HV, Rathod S, Hoshitsuki Ok, Fernandez CA. Amino Acid metabolic vulnerabilities in acute and persistent myeloid leukemias. Entrance Oncol. 2021;11:694526.
Duan Y, Li F, Tan Ok, Liu H, Li Y, Liu Y, et al. Key mediators of intracellular amino acids signaling to mTORC1 activation. Amino Acids. 2015;47:857–67.
Ghosh J, Kobayashi M, Ramdas B, Chatterjee A, Ma P, Mali RS, et al. S6K1 regulates hematopoietic stem cell self-renewal and leukemia upkeep. J Clin Make investments. 2016;126:2621–5.
Dossou AS, Basu A. The rising roles of mTORC1 in macromanaging autophagy. Cancers (Basel). 2019;11:1422.
Rabanal-Ruiz Y, Otten EG, Korolchuk VI. mTORC1 as the principle gateway to autophagy. Essays Biochem. 2017;61:565–84.
Xie Y, Lei X, Zhao G, et al. mTOR in programmed cell demise and its therapeutic implications. Cytokine Development Issue Rev. 2023;71-72:66–81.
Eng CH, Abraham RT. Glutaminolysis yields a metabolic by-product that stimulates autophagy. Autophagy. 2010;6:968–70.
Emadi A, Legislation JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, et al. Asparaginase Erwinia chrysanthemi successfully depletes plasma glutamine in grownup sufferers with relapsed/refractory acute myeloid leukemia. Most cancers Chemother Pharm. 2018;81:217–22.
Chen T, Zhang J, Zeng H, Zhang Y, Zhang Y, Zhou X, et al. Antiproliferative results of L-asparaginase in acute myeloid leukemia. Exp Ther Med. 2020;20:2070–8.
Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, et al. Concentrating on glutaminolysis has antileukemic exercise in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015;126:1346–56.
Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of chosen AML subtypes. Oncotarget. 2016;7:79722–35.
van Gastel N, Schajnovitz A, Vidoudez C, et al. Untargeted metabolomics identifies glutamine metabolism as a driver of chemoresistance in acute myeloid Leukemia. Blood 2017;130:2523.
Freidman NJ, Briot C, Ryan RM. Characterizing sudden interactions of a glutamine transporter inhibitor with members of the SLC1A transporter household. J Biol Chem. 2022;298:102178.
Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, et al. Pharmacological blockade of ASCT2-dependent glutamine transport results in antitumor efficacy in preclinical fashions. Nat Med. 2018;24:194–202.
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in most cancers. Br J Most cancers. 2020;122:4–22.
Zhang HB, Solar ZK, Zhong FM, Yao FY, Liu J, Zhang J, et al. A novel fatty acid metabolism-related signature identifies options of the tumor microenvironment and predicts medical final result in acute myeloid leukemia. Lipids Well being Dis. 2022;21:79.
Tcheng M, Roma A, Ahmed N, Smith RW, Jayanth P, Minden MD, et al. Very lengthy chain fatty acid metabolism is required in acute myeloid leukemia. Blood. 2021;137:3518–32.
Carter JL, Su Y, Qiao X, Zhao J, Wang G, Howard M, et al. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro fashions and mechanisms. Biochem Pharm. 2023;216:115759.
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells will not be enriched for leukemic stem cells however require oxidative metabolism. Most cancers Discov. 2017;7:716–35.
Jones CL, Stevens BM, Culp-Hill R, et al. Inhibition of fatty acid metabolism re-sensitizes resistant leukemia stem cells to venetoclax with azacitidine. Blood. 2019;134:1272.
Wang J, Ye W, Yan X, Guo Q, Ma Q, Lin F, et al. Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia. J Transl Med. 2019;17:149.
Humbert M, Seiler Ok, Mosimann S, Rentsch V, Sharma Ok, Pandey AV, et al. Decreasing FASN expression sensitizes acute myeloid leukemia cells to differentiation remedy. Cell Demise Differ. 2021;28:2465–81.
Pollyea DA, Jones CL, Stevens BM, et al. Relapsed acute myeloid leukemia is much less delicate to venetoclax+ azacitidine as a consequence of leukemia stem cell resistance pushed by fatty acid metabolism and could be overcome by pharmacologic inhibition of CPT1. Blood. 2018;132:432.
Shi J, Fu H, Jia Z, He Ok, Fu L, Wang W. Excessive expression of CPT1A predicts hostile outcomes: a possible therapeutic goal for acute myeloid leukemia. EBioMedicine. 2016;14:55–64.
Thomas D, Wu M, Nakauchi Y, Zheng M, Thompson-Peach CAL, Lim Ok, et al. Dysregulated lipid synthesis by oncogenic idh1 mutation is a targetable artificial deadly vulnerability. Most cancers Discov. 2023;13:496–515.
Tabe Y, Saitoh Ok, Yang H, Sekihara Ok, Yamatani Ok, Ruvolo V, et al. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep. 2018;8:16837.
Mao S, Ling Q, Pan J, Li F, Huang S, Ye W, et al. Inhibition of CPT1a as a prognostic marker can synergistically improve the antileukemic exercise of ABT199. J Transl Med. 2021;19:181.
Peng M, Ghafouri SN, McDermott MSJ, et al. Fatty acid synthase (FASN) inhibitors synergize with carfilzomib (CFZ) in acute myeloid leukemia (AML) and a number of myeloma (MM). Most cancers Res. 2022;82:3023–23.
Krosl J, Bordeleau ME, Moison C, MacRae T, Boivin I, Mayotte N, et al. Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. Blood Adv. 2022;6:509–14.
Hong CS, Jeong E, Boyiadzis M, Whiteside TL. Elevated small extracellular vesicle secretion after chemotherapy by way of upregulation of ldl cholesterol metabolism in acute myeloid leukaemia. J Extracell Vesicles. 2020;9:1800979.
Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue area of interest. Cell Stem Cell. 2016;19:23–37.
Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, et al. Acute myeloid leukemia transforms the bone marrow area of interest right into a leukemia-permissive microenvironment via exosome secretion. Leukemia. 2018;32:575–87.
Kumar B, Orellana M, Brooks J, Madabushi SS, Vishwasrao P, Parra LE, et al. Exosomes-driven lipolysis and bone marrow area of interest transforming helps leukemia growth. Haematologica. 2020;106:1484–8.
Kumar B. Harnessing the metabolic vulnerabilities of leukemia stem cells to eradicate acute myeloid leukemia. Entrance Oncol. 2021;11:632789.
Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129:1320–32.
Tabe Y, Yamamoto S, Saitoh Ok, et al. Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional community supporting survival of acute monocytic leukemia cells. Most cancers Res. 2017;77:1453–64.
Choi SE, Lee SM, Lee YJ, Li LJ, Lee SJ, Lee JH, et al. Protecting position of autophagy in palmitate-induced INS-1 beta-cell demise. Endocrinology. 2009;150:126–34.
Komiya Ok, Uchida T, Ueno T, Koike M, Abe H, Hirose T, et al. Free fatty acids stimulate autophagy in pancreatic β-cells by way of JNK pathway. Biochem Biophys Res Commun. 2010;401:561–7.
Bosc C, Broin N, Fanjul M, Saland E, Farge T, Courdy C, et al. Autophagy regulates fatty acid availability for oxidative phosphorylation via mitochondria-endoplasmic reticulum contact websites. Nat Commun. 2020;11:4056.
Kim KH, Lee MS. Autophagy-a key participant in mobile and physique metabolism. Nat Rev Endocrinol. 2014;10:322–37.
Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Entrance Oncol. 2020;10:155.
Tomaipitinca L, Mandatori S, Mancinelli R, Giulitti F, Petrungaro S, Moresi V, et al. The position of autophagy in liver epithelial cells and its impression on systemic homeostasis. Vitamins. 2019;11:827.
Vegliante R, Di Leo L, Ciccarone F, Ciriolo MR. Hints on ATGL implications in most cancers: past bioenergetic clues. Cell Demise Dis. 2018;9:316.
Khawar MB, Gao H, Li W. Autophagy and lipid metabolism. Autophagy: biology and ailments. Fundamental Sci. 2019;28:359–74.
Li W, He P, Huang Y, Li YF, Lu J, Li M, et al. Selective autophagy of intracellular organelles: current analysis advances. Theranostics. 2021;11:222–56.
Xiao P, Sandhow L, Heshmati Y, Kondo M, Bouderlique T, Dolinska M, et al. Distinct roles of mesenchymal stem and progenitor cells in the course of the improvement of acute myeloid leukemia in mice. Blood Adv. 2018;2:1480–94.
Chen Y, Liang Y, Luo X, Hu Q. Oxidative resistance of leukemic stem cells and oxidative injury to hematopoietic stem cells beneath pro-oxidative remedy. Cell Demise Dis. 2020;11:291.
Jena BC, Das CK, Banerjee I, Bharadwaj D, Majumder R, Das S, et al. TGF-β1 induced autophagy in most cancers related fibroblasts throughout hypoxia contributes EMT and glycolysis by way of MCT4 upregulation. Exp Cell Res. 2022;417:113195.
Patra S, Elahi N, Armorer A, Arunachalam S, Omala J, Hamid I, et al. Mechanisms governing metabolic heterogeneity in breast most cancers and different tumors. Entrance Oncol. 2021;11:700629.
Henkenius Ok, Greene BH, Barckhausen C, Hartmann R, Märken M, Kaiser T, et al. Upkeep of mobile respiration signifies drug resistance in acute myeloid leukemia. Leuk Res. 2017;62:56–63.
Erdem A, Marin S, Pereira-Martins DA, Geugien M, Cunningham A, Pruis MG, et al. Inhibition of the succinyl dehydrogenase advanced in acute myeloid leukemia results in a lactate-fuelled respiratory metabolic vulnerability. Nat Commun. 2022;13:2013.
Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma mannequin of most cancers: position of oxidative stress and ketone manufacturing in fueling tumor cell metabolism. Cell Cycle. 2010;9:3485–505.
Fu Y, Liu S, Yin S, Niu W, Xiong W, Tan M, et al. The reverse Warburg impact is prone to be an Achilles’ heel of most cancers that may be exploited for most cancers remedy. Oncotarget. 2017;8:57813–25.
Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, et al. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016;128:1260–9.
